ICON makes two senior appointments
pharmafile | May 21, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | CRO, ICON, appointment
ICON has appointed Dr Susan Anton as director of epidemiology and risk management practice, and late phase and outcomes research.
It has also appointed Dr Pui Leung as its new senior clinical research physician, in ICON’s development solutions division.
Dr Anton comes to ICON with over 25 years of experience international epidemiologic, health economic, and outcomes research, and other market access initiatives.
She joins ICON from Boehringer Ingelheim, where she was director of US medical outcomes research and registries.
In this role, Dr Anton provided strategic approach, design and analytic guidance for comparative effectiveness research, epidemiologic studies and health technology assessment within their medical outcomes research and registries division.
Prior to Boehringer Dr Anton directed health economic, epidemiologic and outcomes research efforts across therapeutic areas at Bristol-Myers Squibb.
Dr Leung joins ICON with over 23 years of hospital and pharma industry experience in a variety of medical specialties including diabetes, endocrinology and general medicine.
Prior to ICON, Dr Leung gained 10 years of experience as a senior Phase I clinical research physician in two UK CROs, and has been principal investigator in many trials with a variety of different study designs including First in Human studies.
Before joining the pharma industry in 2002, Dr Leung spent 13 years as a hospital physician in the NHS.
Related Content
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
Lonza CEO to step down in 2020
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …